Work

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI Study).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.3_suppl.tps446

Authors: Brian Hemendra Ramnaraign, Steven J. Hughes, Kathryn Hitchcock, Ji-Hyun Lee, Sherise C. Rogers, Z. Hugh Fan, Carmen Joseph Allegra, Jose Gilberto Trevino, Ahmad El-Far, Karen Bullock Russell, Anita Ahmed Turk, David L. DeRemer, Thomas J. George

Institutions: UF Health Cancer Center, University of Florida, Orlando Health, Tallahassee Memorial HealthCare, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Ipsen

OpenAlex ID: W3121624082

Cites:

Cited by: 1

Related to: 10